Obesity Clinical Trial
Official title:
Obesity ACTION Study in Canada
Verified date | July 2019 |
Source | Novo Nordisk A/S |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
This study aims to assess barriers that prevent obesity patients from receiving adequate care
for their condition. The non-interventional study will be administered in the form of a
30-minute, cross-sectional, online survey to various respondents. There is no experimentation
involved in the process of data collection, and each survey poses minimal human risk.
The study will evaluate lifestyle habits and weight management strategies perceived and/or
practiced by each of 3 stakeholders in obesity: Patients (People with obesity), Providers,
and Employers. A customized survey will be administered to each of the 3 stakeholders, and
data will be analyzed based on respondents' answers.
Status | Completed |
Enrollment | 2545 |
Est. completion date | October 11, 2017 |
Est. primary completion date | October 11, 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A and older |
Eligibility |
Inclusion criteria The following inclusion criteria will be imposed for HCPs: - Practice in Canada - Spends at least 70% of time in direct patient care - Seen at least 100 patients in past month - Seen at least 10 patients in past month needing weight management - In practice 2-35 years - Not affiliated with Pharmaceutical, Market Research (MR) or Advertising Firms - PCP - Physician, RN / NP / LPN, or PA, Dietitians - PCP - Specialty is FP, IM, GP - Obesity Specialist - Physician, RN / NP / LPN, or PA - Obesity Specialist - Specialty is FP, IM, GP, endocrinology, bariatrics, or bariatric surgery - Obesity Specialist - Currently practice as an obesity medicine or weight loss management specialist The following inclusion criteria will be imposed for PwOs (people with obesity): - Age at least 18 years - Lives in Canada - Recruitment will target a nationally representative Canada sample. Demographic indicators will be monitored throughout recruitment. - Current BMI 30 kg/sqm or greater, not extremely fit/body building - Sub-category - Maintaining weight loss: Lost at least 10% of body weight in the past 3 years and has kept weight off for at least a year - Sub-category - Treatment Seeking: Has committed to a plan to lose weight, or has successfully lost weight (self-report) or has spoken to an HCP about weight loss plan in the last 6 months. The following inclusion criteria will be imposed for employers: - Age at least 18 years - Works in a Canadian province - Company offers health insurance - Responsible for making or influencing decisions about health insurance or health and wellness programs - Works in a company that has 20 or more employees - Believes there is a weight issue (attitudinal agreement) - Not affiliated with Pharmaceutical, Market Research (MR) or Advertising Firms Exclusion criteria Any respondent who work works for a pharmaceutical, health insurance, research, or advertising company will be excluded; as there may be self-presentation effects that could alter the interview questions. |
Country | Name | City | State |
---|---|---|---|
Canada | Novo Nordisk Investigational Site | Edmonton | Alberta |
Lead Sponsor | Collaborator |
---|---|
Novo Nordisk A/S |
Canada,
Sharma AM, Bélanger A, Carson V, Krah J, Langlois MF, Lawlor D, Lepage S, Liu A, Macklin DA, MacKay N, Pakseresht A, Pedersen SD, Ramos Salas X, Vallis M. Perceptions of barriers to effective obesity management in Canada: Results from the ACTION study. Cl — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Awareness associated with the care and management of obesity among people with obesity, clinicians and employers | Cross-sectional 30-minute online survey of lifestyle habits and weight management conducted among stakeholders in obesity (clinicians, employers and people with obesity) | From the first interview on day 1 until the last interview on day 30 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04243317 -
Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults
|
N/A | |
Recruiting |
NCT04101669 -
EndoBarrier System Pivotal Trial(Rev E v2)
|
N/A | |
Terminated |
NCT03772886 -
Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball
|
N/A | |
Completed |
NCT03640442 -
Modified Ramped Position for Intubation of Obese Females.
|
N/A | |
Completed |
NCT04506996 -
Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2
|
N/A | |
Recruiting |
NCT06019832 -
Analysis of Stem and Non-Stem Tibial Component
|
N/A | |
Active, not recruiting |
NCT05891834 -
Study of INV-202 in Patients With Obesity and Metabolic Syndrome
|
Phase 2 | |
Active, not recruiting |
NCT05275959 -
Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI)
|
N/A | |
Recruiting |
NCT04575194 -
Study of the Cardiometabolic Effects of Obesity Pharmacotherapy
|
Phase 4 | |
Completed |
NCT04513769 -
Nutritious Eating With Soul at Rare Variety Cafe
|
N/A | |
Withdrawn |
NCT03042897 -
Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer
|
N/A | |
Completed |
NCT03644524 -
Heat Therapy and Cardiometabolic Health in Obese Women
|
N/A | |
Recruiting |
NCT05917873 -
Metabolic Effects of Four-week Lactate-ketone Ester Supplementation
|
N/A | |
Active, not recruiting |
NCT04353258 -
Research Intervention to Support Healthy Eating and Exercise
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Recruiting |
NCT03227575 -
Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control
|
N/A | |
Completed |
NCT01870947 -
Assisted Exercise in Obese Endometrial Cancer Patients
|
N/A | |
Recruiting |
NCT05972564 -
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
|
Phase 1/Phase 2 | |
Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
Recruiting |
NCT05371496 -
Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction
|
Phase 2 |